All News

Lab work

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring

d Blair Solow, MD, MSc
Sep 21, 2023

We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment. 

Read Article
TNR MTX Panel

TNR: Decisions in Methotrexate

d Jack Cush, MD
Sep 20, 2023

This Tuesday Night Rheumatology panel discussion on "Methotrexate Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer.

Read Article
Tomorrow! Join us for Decisions in MTX at 7pm ET. https://t.co/SRjj64QPeW https://t.co/JSAPjDxKYn
RheumNow Dr. John Cush ( View Tweet)
Sep 18, 2023
QD Clinic: RA and medication induced ulcers Dr. Bella Mehta, a rheumatologist from New York, presents this QD clinic on medication induced ulcers as part of RheumNow's Hard Decisions in #RA campaign. https://t.co/AVjUYltVvK https://t.co/mVI1oQob0Z
RheumNow Dr. John Cush ( View Tweet)
Sep 18, 2023
Watch Drs. Janet Pope and Alvin Wells debate Triple DMARD Therapy Drs. Janet Pope and Alvin Wells debate triple DMARD therapy. These and more debates and perspectives on Hard Decisions in #RA now available. https://t.co/f59Wh3lnHX @janetbirdope @alvinwellsmd https://t.co/H2F4wOElSw
RheumNow Dr. John Cush ( View Tweet)
Sep 16, 2023
Prospective cohort study of 41 Stills Dz pts w/ ILD - 85% had 1+MAS & 41% with adverse reactions to a biologic. 93% were alive w/ median F/U 3 years, but 37% progressed to chronic lung dz (O2, or vent) & 84% were HLA-DRB1*15 https://t.co/fo44fgKh8m https://t.co/xa9g4Slr1H
RheumNow Dr. John Cush ( View Tweet)
Sep 14, 2023
EarlyRA.TNR

TNR: Early RA - Referrals and Treatment

d Jack Cush, MD
Sep 13, 2023

This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.

The​ Panel discussed Rheumatologists ​views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.

Read Article
heart-665185__180.jpg

Hydroxychloroquine Adherence Lowers Cardiovascular Risks

d Jack Cush, MD
Sep 11, 2023

Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

Read Article
Full read review of Colchicine drug interactions - primarily inhibitors of CYP3A4 (includes statins, amiodarone, cyclosporine, voriconazole). Signs of colchicine toxicity include diarrhea, myalgia, weakness, myoglobinuria, BM suppression/cytopenias. https://t.co/qddOnCJc5x https://t.co/2yGlr4nXmF
RheumNow Dr. John Cush ( View Tweet)
Sep 09, 2023
SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81
RheumNow Dr. John Cush ( View Tweet)
Sep 09, 2023
RheumNow Podcast square

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

d Jack Cush, MD
Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article
QD Clinic - MTX Pearls Active RA needs to change meds but cannot handle higher doses of MTX. #RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS. https://t.co/ExwgtWjeNj https://t.co/0JO84tMV0O
RheumNow Dr. John Cush ( View Tweet)
Sep 08, 2023
Oral Surveillance Changes in Advanced Therapy Use in #RA The safety of tofacitinib and TNF inhibitors was studied in high risk RA patients in the ORAL Surveillance study. Read more.... https://t.co/2ZyB0xow6B https://t.co/mB5R0HfaWq
RheumNow Dr. John Cush ( View Tweet)
Sep 08, 2023
Miss this week's TNR on Oral Surveillance Revisited? Watch the playback here. Join an hour long panel discussion featuring Drs. Janet Pope, Jeff Curtis, Jon Giles and Roy Fleischmann. TNR is sponsored by BMS. #RA https://t.co/Q6zptUxDaW https://t.co/HPuQXWZSBr
RheumNow Dr. John Cush ( View Tweet)
Sep 07, 2023
#RA QD Clinic - RA & Vaccination An RA patient needs vaccination - how do you handle the meds? RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS. https://t.co/ktNZIpInMS https://t.co/fsobHjTq1v
RheumNow Dr. John Cush ( View Tweet)
Sep 06, 2023
Anifrolumab targets type I IFN pathway. In #SLE Trials, pts on ANIF had as much as 8-fold higher rate of Herpes zoster. HZ incidence is 6.9 vs 1.5/100 PYs on ANIF vs PBO. Other drugs may affect IFN - sifalimumab litifilimab, daxdilimab, deucravacitinib https://t.co/V6BceVjRDc https://t.co/lcjbjS9uZt
RheumNow Dr. John Cush ( View Tweet)
Sep 04, 2023
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

d Jack Cush, MD
Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl
RheumNow Dr. John Cush ( View Tweet)
Aug 31, 2023
Gout pills injection

SGLT2 Inhibitors as Gout Treatment

d MedPage Today
Aug 30, 2023

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.

Read Article
Posthoc analysis 2 phase III RCTs of ABAtacept x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA+MTX Rx pts were compared & there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies https://t.co/lBJrPzm5S1 https://t.co/RM542Hl8Fu
RheumNow Dr. John Cush ( View Tweet)
Aug 30, 2023

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×